Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Lymphoid 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Somatostatinoma 1Pituitary Neoplasms 1Growth Hormone-Secreting Pituitary Adenoma 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1

Interventions

telotristat ethyl 4lutetium Lu 177 dotatate 43-Iodobenzylguanidine 3vandetanib 2pasireotide 2gallium Ga 68 dotatate 2Temozolomide 2Octreotide 2Biological Therapy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vatalanib 1trametinib 1pembrolizumab 1lanreotide 1fosbretabulin 1farletuzumab 1dabrafenib 1combretastatin 1ceritinib 1antineoplaston AS 2-1 1antineoplaston A10 1Tretinoin 1Tranexamic Acid 1Solutions 1Saline Solution 1Panitumumab 1Paclitaxel 1Microarray Analysis 1Isotretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Complementary Therapies × Endocrine × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡